Highlights Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Delayed Warsaw S.E. Other stock markets 10:17:23 28/06/2024 BST			5-day change	1st Jan Change
50 ^PLN	0.00%		-0.20%	-13.04%

05-17	Transcript : Ryvu Therapeutics S.A. - Special Call
03-13	Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	03-06	CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	02-14	CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	01-31	CI
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	12-07	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23/10/23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/09/23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	11/12/22	CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	30/11/22	MT
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	30/11/22	MT
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	30/11/22	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23/11/22	CI
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	03/11/22	CI
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium	26/10/22	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	28/09/22	CI
Poland's Ryvu Therapeutics Bags $22 Million EU Financing To Develop New Cancer Drugs	17/08/22	MT
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress	10/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Highlights

Filters